The NIH Somatic Cell Genome Editing (SCGE) Program



April 23,2018 NIST Conference Colin Fletcher, Ph.D. NHGRI



National Institutes of Health Office of Strategic Coordination - The Common Fund

NIH Planning Workshop for the SCGE Program July 24, 2017

Major Gaps Identified:

Relevant human and animal models systems for pre-clinical testing Cell- and tissue-specific delivery systems Error-free editing machinery (nuclease alternatives) Standardized assays for measuring genetic off-target effects Long-term cell tracking assays

Mission:

"The focus of the Somatic Cell Genome Editing program is to dramatically accelerate the translation of these technologies to the clinic for treatment of as many genetic diseases as possible." NIH Director Francis S. Collins, M.D., Ph.D



SCGE Program Goals

- Lower the Barriers for New Gene Editing Therapies by:
- Testing Gene Editing Reagents/Delivery Systems in Animal Models Assessing Unintended Biological Effects Improving *In Vivo* Delivery of Genome Editing Machinery Expanding the Human Genome Engineering Toolkit Coordinating Partnerships and Disseminating Information



SCGE Program Structure

The SCGE program will utilize milestone-driven Cooperative Agreements and award ~\$196M over 5 years. Currently, applications are in review, and FOA reissues are expected in the near future.

Awardees will be required to collaborate and share data, resources and information with other consortium members and the Dissemination and Coordinating Center.


Resources and information generated by the SCGE will be disseminated by the Dissemination and Coordinating Center to the broader research community through the SCGE Toolkit for Therapeutic Genome Editing ("SCGE Toolkit")



SCGE Program Interactions

SCGE Dissemination & Coordinating Center

- Facilitate interactions and communication between consortium components
 - Disseminate a SCGE Toolkit to the research community



SCGE Program Focus

SCGE Dissemination & Coordinating Center (9)

n e w g e

n o

m


e e

d

t o

S

5




cell and tissue platforms to detect adverse biological consequences (43)

large and small animal reporter systems (30)



Thank you!







Program Contacts

FOAs RM-18-012 and RM-18-013 (Animals):

Oleg Mirochnitchenko, Ph.D. Office of Research Infrastructure Programs Office of the Director National Institutes of Health (NIH) <u>oleg.mirochnitchenko@nih.gov</u>

FOA RM-18-017 (Editors):

Betty Poon, Ph.D. Program Director Targeted Interventions Branch NIAID poonb@niaid.nih.gov

Common Fund Program:

Mary Perry, Ph.D. Program Leader Office of Strategic Coordination Office of the Director National Institutes of Health (NIH) perryma@mail.nih.gov

FOA RM-18-016 (Delivery Systems):

P.J. Brooks, Ph.D. Program Coordinator Division of Clinical Innovation and Office of Rare Diseases Research NCATS pjbrooks@mail.nih.gov

FOA RM-18-015 (Biological Systems):

John Sheridan, Ph.D. Program Director Division of Lung Diseases NHLBI <u>john.sheridan@nih.gov</u>

FOA RM-19-018 (SCGE DCC):

Colin Fletcher, Ph.D. Program Director Division of Genome Sciences NHGRI

colin.fletcher@nih.gov

NIH Common Fund SCGE Program Website: https://commonfund.nih.gov/editing

SCGE "Ask Anything" Mailbox:



SCGEprogram@nih.gov